pfizer-j_j-biosimilar.jpeg - Higher Ground Times

In this Monday, Nov. 23, 2015, photo, flags fly in front of Pfizer World Headquarters, in New York. Drugmaker Pfizer said that in November 2016 it will launch a less-expensive version of rival Johnson &amp; Johnson’s blockbuster immune disorder drug, Remicade. Pfizer’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. (AP Photo/Mark Lennihan) — In this Monday, Nov. 23, 2015, photo, flags fly in front of Pfizer World Headquarters, in New York. Drugmaker Pfizer said that in November 2016 it will launch a less-expensive version of rival Johnson & Johnson’s blockbuster immune disorder drug, Remicade. Pfizer’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. (AP Photo/Mark Lennihan)

Featured Photo Galleries

As search for Helene's victims drags into second week, sheriff says rescuers 'will not rest'

Dockworkers' union suspends strike until Jan. 15 to allow time to negotiate new contract

What happens when shipping containers are lost at sea?

Iran and Israel swap threats following missile barrage

MiddleIran fires missiles at Israel after Israeli ground raids into Lebanon

Dockworkers at ports from Maine to Texas go on strike, a standoff risking new shortages

Rookie QB Daniels stars again in desert return, Commanders beat Cardinals 42-14 for 3rd straight

Supplies rushed to communities isolated by Helene as death toll rises to nearly 100

Israeli airstrike levels apartment building in central Beirut

Rescuers race to free people trapped by Hurricane Helene after storm kills at least 40 in 4 states

Helene weakens to a tropical storm with maximum sustained winds of 70 mph over Georgia

Hurricane Helene threatens 'unsurvivable' storm surge and vast inland damage, forecasters say